SARS-CoV-2 infection in patients with primary central nervous system lymphoma in the vaccination era

Alice Laurenge,Renata Ursu,Emeline Tabouret,Vincent Harlay,Guido Ahle,Sylvain Choquet,Carole Soussain,Cécile Moluçon-Chabrot,Bertrand Mathon,Karima Mokhtari,Valérie Pourcher,Lucia Nichelli,Stéphane Marot,Mehdi Touat,Khê Hoang-Xuan,Caroline Houillier
DOI: https://doi.org/10.1080/10428194.2022.2131420
2022-11-03
Abstract:The authors would like to thank the patients who took part in the study and their families, as well as the staff, research coordinators, and investigators at each participating institution. We gratefully acknowledge the support of the CoCo Neurosciences study group and the LOC network. All authors report no disclosures relevant to the manuscript. MT has a consulting or advisory role with Agios Pharmaceutical, Integragen, and Taiho Oncology, and research funding from Sanofi. The study was conducted in compliance with the Declaration of Helsinki. Approval was obtained from the local ethics committee (IRB approval 2020CER-202028). AL, CH and KHX designed the study. AL, CH, RU, ET, VH, GA, SC, CS, CMC, BM, KM, VP, LN, SM and MT collected the data. AL and CH reviewed and analyzed the clinical data. AL and CH wrote the initial draft, with input from all authors. All authors participated in data analysis, reviewed and approved the final manuscript.
oncology,hematology
What problem does this paper attempt to address?